Analysis of Genentech’s corporate strategy, marketed portfolio, pipeline potential and financial position in 2007 and to 2013

High impact company profile available at BioMarket

Overview of adjuvants for prophylactic vaccines with detailed profiles and critical assessment of key products. Discussion of the regulatory environment with strategic recommendations for adjuvant developers to optimize chances of market approval.

Iomai Corporation: Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

The report "Asia Pacific Biotechnology Market (2007-2010)" provides an updated and detailed overview of the Asia-Pacific Biotechnology industry.

This analysis examines the historical and forecast performance for Biogen Idec in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year

A forecast and analysis of information technology (IT) spending in the US and Canada healthcare provider and payer industry.

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of peptic ulcer or gastric ulcer or duodenal ulcer drugs by company and by stage as well as a summary of the latest news and developments in this a

This analysis examines the historical and forecast performance for Watson in the generic pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sale

The Menarini Pharma Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

Provides analysis of key events and their impact on the Parkinson’s disease market since 2007. Includes an event-based, indication- and country-specific 10 year forecast of both pipeline and marketed products to 2017 in the seven major markets (7

Analysis of the insulin antidiabetic pipeline across seven major markets.

This report provides an overview of the pharmaceutical distribution model in Europe and the US, and highlights recent changes in the supply chain that impact on the industry, particularly with regards to parallel trade and counterfeit strategies.

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of ulcers drugs by company and by stage as well as a summary of the latest news and developments in this area.

This market is entering into a crucial period with many key products losing patent protection, facing heavy generic competition.

A report that provides a detailed examination of the current market for immunomodulatory therapies.

The Bayer Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

The Pfizer Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

The Solvay Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

High impact company profile available at BioMarket

Orexigen Therapeutics Inc: Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

High impact company profile available at BioMarket

Danaher is a diversified technology company engaged in designing, manufacturing and marketing of professional, medical, industrial and consumer products with strong brand names and significant market positions.

The current epilepsy market boasts a wide range of treatment options and has recently reached a state of maturity. The market value across the 7MM grew by just 2.3% from 2005 to $3.2 billion in 2006. However, imminent change to the market in the near t

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of bronchospasm drugs by company and by stage as well as a summary of the latest news and developments in this area.

In 2006 visiongain valued this market at $37406m, But do you know how the blood diseases treatments market will fare 5, 10 and 15 years from now?

India, a US$ 8.2 Billion pharmaceutical market, represents one of the most emerging pharmaceutical markets in the world.

With deals increasing in terms of number and value, partnering at early stage development is now an integral component of pharmaceutical and biotech business strategy.

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of obesity drugs by company and by stage as well as a summary of the latest news and developments in this area.